NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer

NICE Favors Adding Rubraca to NHS England to Treat Relapsed Ovarian Cancer
The U.K.'s National Institute for Health and Care Excellence, widely known as NICE, is recommending that Clovis Oncology's Rubraca (rucaparib) be available as a maintenance therapy for women with recurrent epithelial ovarian, fallopian tube and peritoneal cancer who responded to platinum-based chemotherapy, regardless of their BRCA status or previous lines of treatment. NICE's appraisal helps to assure that patients in England will have access, at reduced or no cost, to Rubraca as a maintenance option under the Cancer Drugs Fund (CDF), the National Health Service (NHS) reserve to fund cancer therapies. An estimated 6,400 women are diagnosed with ovarian cancer in the U.K. every year. Despite advancements in treatment and care, relapse rates continue to be very high. Nearly 70% of patients treated with surgery and first-line chemotherapy experience a return of their cancer within three years. We welcome "the availability of rucaparib via the CDF as an option for maintenance treatment of platinum-sensitive relapsed high grade serous epithelial ovarian cancer regardless of BRCA status or line of treatment in the relapsed maintenance setting,” Victoria Clare, CEO of the ovarian cancer charity Ovacome, said in a press release. “It is vital that the expansion of available maintenance options continues as maintenance treatments extend the time between chemotherapies. Many women with relapsed ovarian cancer know that they are facing a future of managing their disease as a chronic illness,” Clare added. The European Union's conditional approval is based on data from the pivotal ARIEL3 Phase 3 trial (NCT01968213), where Rubraca maintenance extended the time patients lived without disease progression from 5.4 months to 10.8 months — representing a 64% r
Subscribe or to access all post and page content.